Osteoporosis

Weight Loss Drugs and Type 1 Diabetes Risks

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has surged among people with type 1 diabetes, largely driven by rising obesity rates in this population . These drugs, originally developed for type 2 diabetes and obesity, offer promising benefits such as weight loss and improved glycemic control but also carry potential risks that are not yet fully understood in type 1 diabetes . As more patients with type 1 diabetes seek these medications, it is crucial to understand their effects, safety concerns, and clinical considerations .